Testosterone blunts feedback inhibition of growth hormone secretion by experimentally elevated insulin-like growth factor-I concentrations

Johannes D Veldhuis, Stacey M. Anderson, Ali Iranmanesh, Cyril Y. Bowers

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The present study tests the hypothesis that a high dose of testosterone (Te) drives GH and IGF-I production, in part, by blunting autonegative feedback by the end-product peptide. To this end, we infused saline or recombinant human IGF-I (10 μg/kg·h iv for 6 h) in seven healthy men ages 51-72 yr after administration of placebo (Pl) and Te in randomized order. GH release was quantitated fasting before and after injection of GHRH (1 μg/kg). Statistical analyses disclosed that Te vs. Pl: 1) increased the mean concentration of GH from 0.15 ± 0.045 to 0.48 ± 0.11 μg/liter (P = 0.007) and IGF-I from 108 ± 5.0 to 124 ± 4.1 (P = 0.047) without altering GHRH-induced GH release; 2) elevated the GH nadir from 0.13 ± 0.03 to 0.23 ± 0.06 μg/liter (P < 0.05) in the control session and from 0.06 ± 0.02 to 0.14 ± 0.04 μg/liter (P = 0.038) during IGF-I infusion; 3) augmented GHRH-stimulated GH release from 3.0 ± 0.56 (Pl) to 3.7 ± 0.52 μg/liter (Te) (P < 0.05) during IGF-I infusion; and 4) did not influence estimated IGF-I kinetics. In summary, supplementation of a high dose of Te in middle-aged and older men attenuates IGF-I feedback-dependent inhibition of nadir and peak GH secretion. Both effects of Te differ from those reported recently for estradiol in postmenopausal women. Accordingly, we postulate that Te and estrogen modulate IGF-I negative feedback differentially.

Original languageEnglish (US)
Pages (from-to)1613-1617
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume90
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Insulin-Like Growth Factor I
Growth Hormone
Testosterone
Feedback
Placebos
Inhibition (Psychology)
Estradiol
Fasting
Estrogens
Peptides
Injections
Kinetics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Testosterone blunts feedback inhibition of growth hormone secretion by experimentally elevated insulin-like growth factor-I concentrations. / Veldhuis, Johannes D; Anderson, Stacey M.; Iranmanesh, Ali; Bowers, Cyril Y.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 90, No. 3, 03.2005, p. 1613-1617.

Research output: Contribution to journalArticle

Veldhuis, Johannes D ; Anderson, Stacey M. ; Iranmanesh, Ali ; Bowers, Cyril Y. / Testosterone blunts feedback inhibition of growth hormone secretion by experimentally elevated insulin-like growth factor-I concentrations. In: Journal of Clinical Endocrinology and Metabolism. 2005 ; Vol. 90, No. 3. pp. 1613-1617.
@article{e79b3760109d4b6aa159f7fb5fce46b8,
title = "Testosterone blunts feedback inhibition of growth hormone secretion by experimentally elevated insulin-like growth factor-I concentrations",
abstract = "The present study tests the hypothesis that a high dose of testosterone (Te) drives GH and IGF-I production, in part, by blunting autonegative feedback by the end-product peptide. To this end, we infused saline or recombinant human IGF-I (10 μg/kg·h iv for 6 h) in seven healthy men ages 51-72 yr after administration of placebo (Pl) and Te in randomized order. GH release was quantitated fasting before and after injection of GHRH (1 μg/kg). Statistical analyses disclosed that Te vs. Pl: 1) increased the mean concentration of GH from 0.15 ± 0.045 to 0.48 ± 0.11 μg/liter (P = 0.007) and IGF-I from 108 ± 5.0 to 124 ± 4.1 (P = 0.047) without altering GHRH-induced GH release; 2) elevated the GH nadir from 0.13 ± 0.03 to 0.23 ± 0.06 μg/liter (P < 0.05) in the control session and from 0.06 ± 0.02 to 0.14 ± 0.04 μg/liter (P = 0.038) during IGF-I infusion; 3) augmented GHRH-stimulated GH release from 3.0 ± 0.56 (Pl) to 3.7 ± 0.52 μg/liter (Te) (P < 0.05) during IGF-I infusion; and 4) did not influence estimated IGF-I kinetics. In summary, supplementation of a high dose of Te in middle-aged and older men attenuates IGF-I feedback-dependent inhibition of nadir and peak GH secretion. Both effects of Te differ from those reported recently for estradiol in postmenopausal women. Accordingly, we postulate that Te and estrogen modulate IGF-I negative feedback differentially.",
author = "Veldhuis, {Johannes D} and Anderson, {Stacey M.} and Ali Iranmanesh and Bowers, {Cyril Y.}",
year = "2005",
month = "3",
doi = "10.1210/jc.2004-1303",
language = "English (US)",
volume = "90",
pages = "1613--1617",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Testosterone blunts feedback inhibition of growth hormone secretion by experimentally elevated insulin-like growth factor-I concentrations

AU - Veldhuis, Johannes D

AU - Anderson, Stacey M.

AU - Iranmanesh, Ali

AU - Bowers, Cyril Y.

PY - 2005/3

Y1 - 2005/3

N2 - The present study tests the hypothesis that a high dose of testosterone (Te) drives GH and IGF-I production, in part, by blunting autonegative feedback by the end-product peptide. To this end, we infused saline or recombinant human IGF-I (10 μg/kg·h iv for 6 h) in seven healthy men ages 51-72 yr after administration of placebo (Pl) and Te in randomized order. GH release was quantitated fasting before and after injection of GHRH (1 μg/kg). Statistical analyses disclosed that Te vs. Pl: 1) increased the mean concentration of GH from 0.15 ± 0.045 to 0.48 ± 0.11 μg/liter (P = 0.007) and IGF-I from 108 ± 5.0 to 124 ± 4.1 (P = 0.047) without altering GHRH-induced GH release; 2) elevated the GH nadir from 0.13 ± 0.03 to 0.23 ± 0.06 μg/liter (P < 0.05) in the control session and from 0.06 ± 0.02 to 0.14 ± 0.04 μg/liter (P = 0.038) during IGF-I infusion; 3) augmented GHRH-stimulated GH release from 3.0 ± 0.56 (Pl) to 3.7 ± 0.52 μg/liter (Te) (P < 0.05) during IGF-I infusion; and 4) did not influence estimated IGF-I kinetics. In summary, supplementation of a high dose of Te in middle-aged and older men attenuates IGF-I feedback-dependent inhibition of nadir and peak GH secretion. Both effects of Te differ from those reported recently for estradiol in postmenopausal women. Accordingly, we postulate that Te and estrogen modulate IGF-I negative feedback differentially.

AB - The present study tests the hypothesis that a high dose of testosterone (Te) drives GH and IGF-I production, in part, by blunting autonegative feedback by the end-product peptide. To this end, we infused saline or recombinant human IGF-I (10 μg/kg·h iv for 6 h) in seven healthy men ages 51-72 yr after administration of placebo (Pl) and Te in randomized order. GH release was quantitated fasting before and after injection of GHRH (1 μg/kg). Statistical analyses disclosed that Te vs. Pl: 1) increased the mean concentration of GH from 0.15 ± 0.045 to 0.48 ± 0.11 μg/liter (P = 0.007) and IGF-I from 108 ± 5.0 to 124 ± 4.1 (P = 0.047) without altering GHRH-induced GH release; 2) elevated the GH nadir from 0.13 ± 0.03 to 0.23 ± 0.06 μg/liter (P < 0.05) in the control session and from 0.06 ± 0.02 to 0.14 ± 0.04 μg/liter (P = 0.038) during IGF-I infusion; 3) augmented GHRH-stimulated GH release from 3.0 ± 0.56 (Pl) to 3.7 ± 0.52 μg/liter (Te) (P < 0.05) during IGF-I infusion; and 4) did not influence estimated IGF-I kinetics. In summary, supplementation of a high dose of Te in middle-aged and older men attenuates IGF-I feedback-dependent inhibition of nadir and peak GH secretion. Both effects of Te differ from those reported recently for estradiol in postmenopausal women. Accordingly, we postulate that Te and estrogen modulate IGF-I negative feedback differentially.

UR - http://www.scopus.com/inward/record.url?scp=15944418597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15944418597&partnerID=8YFLogxK

U2 - 10.1210/jc.2004-1303

DO - 10.1210/jc.2004-1303

M3 - Article

C2 - 15585557

AN - SCOPUS:15944418597

VL - 90

SP - 1613

EP - 1617

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -